HTGF exits Kinaxo

There was also an earn-out agreement made of €4m in cash, which is due if the company reaches its performance targets. The issue of shares is bound on a lock-up agreement. The investor says it has made an attractive multiple with the exit of Kinaxo. The deal will close in April 2011.

Munich-based Kinaxo is a drug discovery and early development partner for pharmaceutical and biotechnology companies.

The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.

If you have any information regarding this transaction, please contact Diana Petrowicz on +44 20 7004 7505 or diana.petrowicz@incisivemedia.com

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Exits
• High-Tech Gründerfonds
• Germany